Press release
Integrating Drug-Drug Interactions and Lifestyle Factors with Drug-Gene Interactions Provided by Castle Biosciences’ IDgenetix® Test Significantly Impacted the Number of Drug Recommendations for Patients with Moderate to Severe Depression
IDgenetix is a clinically validated pharmacogenomic (PGx) test that incorporates the results of drug-gene interactions with drug-drug interactions and
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"\nIDgenetix is a clinically validated pharmacogenomic (PGx) test that incorporates the results of drug-gene interactions with drug-drug interactions and lifestyle factors, such as smoking and use of over-the-counter medicines and dietary supplements, to provide medication recommendations for patients with mental health conditions\n\n\n FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced data from a study showing the addition of drug-drug interactions and lifestyle factors to drug-gene interactions provided by its IDgenetix® test significantly impacted the number of drug recommendations and contributed to improved remission rates for patients with moderate to severe depression. The data was shared at Psych Congress 2023 in a poster titled, “The Importance of Incorporating Drug-Drug Interactions and Lifestyle Factors in Pharmacogenomics-Guided Medication Management for Patients with Major Depressive Disorder in a Randomized Controlled Trial.”\n\n\n“There are many factors that can impact how a patient responds to and metabolizes mental health medication, such as their genetics, other drugs being taken and lifestyle choices like smoking,” said Robert Cook, Ph.D., senior vice president of research and development at Castle Biosciences. “This study reinforces the value of our IDgenetix test in providing personalized information for each patient, taking drug-gene, drug-drug and lifestyle factor interactions into account, to guide optimal medication selection that may help patients with depression achieve faster remission from their symptoms.”\n\n\nIDgenetix is supported by a published randomized controlled trial (RCT) showing that patients whose medication management was guided by the test were 2.65 times more likely to achieve remission of depressive symptoms compared to patients whose medication management was guided by the standard-of-care, trial-and-error approach.1 The study shared at Psych Congress 2023 evaluated the contribution of drug-gene, drug-drug and lifestyle factors to IDgenetix-guided medication management in patients with moderate to severe depression from this RCT (n=261).\n\n\nThe non-genetic information (drug-drug interactions and lifestyle factors) accounted for 43% of all drug recommendations in...